Methyl-p-Hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: Correlation with biological and clinico-pathological parameters
✍ Scribed by Franco O. Ranelletti; Giovanni Scambia; Pierluigi Benedetti Panici; Mauro Piantelu; Gabriella Ferrandina; Giuseppe D'agostino; Rosa De Vincenzo; Alessandro Rinelli; Giulio Isola; Salvatore Mancuso
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- French
- Weight
- 611 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
We examined the levels of activity of methyl-p-hydroxyphenyllactate esterase (MeHPLA-ase) and cytosolic Type-ll-estrogenbinding sites (Type-ll EBS) in 61 and 71 cases, respectively, of primary ovarian cancer. MeHPlA-ase activity and Type-ll EBS were seen to by asymmetrically distributed, in that levels were skewed towards the lower values. A statistically significant direct correlation was found between MeHPLA-ase activity and Type-ll EBS. MeHPLA-are activity and Type-I1 EBS were inversely correlated with ER and PR levels and showed a trend towards inverse correlation with the percentage of cells in S-phase of the cell cycle. MeHPLA-ase activity and Type-ll EBS did not correlate with clinico-pathological parameters. The median MeHPlA-are activity tended to be higher in responders than in unresponsive patients, but statistical significance was not reached. Higher Type-11-EBS levels were found in cases showing complete and partial response to chemotherapy than in cases which did not respond. A statistically significant relationship was found between high MeHPlA-are activity and longer overall survival.